871022-62-7

Basic information

• Product Name: TERT-BUTYL (4-FLUOROPIPERIDIN-4-YL)METHYLCARBAMATE
• Synonyms: TERT-BUTYL (4-FLUOROPIPERIDIN-4-YL)METHYLCARBAMATE;4-(Boc-aMinoMethyl)-4-fluoropiperidine;[(4-Fluoro-4-piperidinyl)methyl]carbamic acid 1,1-dimethylethyl ester;4-[(tert-Butoxycarbonylamino)methyl]-4-fluoropiperidine;tert-butyl N-[(4-fluoropiperidin-4-yl)methyl]carbamate;tert-butyl (4-Fluoropiperidin-4-yl)methylcarbamate hydrochloride
• CAS NO: 871022-62-7
• Molecular Formula: C₁₁H₂₁FN₂O₂
• Molecular Weight: 232.297
• Mol File: 871022-62-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 282.6°C at 760 mmHg
• Flash Point: 124.7°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 0.00332mmHg at 25°C
• Refractive Index: 1.473
• PKA: 12.72±0.46(Predicted)
• CAS DataBase Reference: TERT-BUTYL (4-FLUOROPIPERIDIN-4-YL)METHYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL (4-FLUOROPIPERIDIN-4-YL)METHYLCARBAMATE(871022-62-7)
• EPA Substance Registry System: TERT-BUTYL (4-FLUOROPIPERIDIN-4-YL)METHYLCARBAMATE(871022-62-7)

Safety Data

• Hazardous Substances Data: 871022-62-7(Hazardous Substances Data)

Usage

Uses

tert-?Butyl (4-?Fluoro-?4-?piperidinyl)?methylcarbamate is a reagent used in the preparation of cyanophenylglycine derivatives which may act as reversible inhibitors of lysine demethylase 1 which is involved in the differentiation of leukemia stem cells in ACM.

InChI:InChI=1/C11H21FN2O2/c1-10(2,3)16-9(15)14(4)11(12)5-7-13-8-6-11/h13H,5-8H2,1-4H3

Upstream product

• 455267-63-7 benzyl 4-(azidomethyl)-4-fluoropiperidine-1-carboxylate 
• 240400-84-4 benzyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate 
• 77211-75-7 benzyl 1-oxa-6-aza-spiro[2.5]octane-6-carboxylate 
• 871022-60-5 N-benzoyl-4-tert-butoxycarbonylaminomethyl-4-fluoropiperidine 

Relevant articles and documents

HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2

A compound of formula (I):wherein Ring A, Q, R1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R11,X, a,b, c and d are as defined in the specification.

Benzimidazolone carboxylic acid derivatives

This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.